Gossamer Bio, Inc. (GOSS) — SEC Filings

Latest SEC filings for Gossamer Bio, Inc. (GOSS), explained in plain English.

Sentiment Overview: 2 bullish, 6 bearish, 23 neutral

Recent Filings (31)

• Gossamer Bio Faces Delisting Concerns — 8-K · 2026-04-09T16:01:13-04:00 [bearish] Risk: high
  Gossamer Bio, Inc. filed an 8-K on April 9, 2026, to report a notice of delisting or failure to satisfy a continued listing rule or standard, as of April 8, 202
• Gossamer Bio's Losses Mount Amid Soaring R&D, Cash Dwindles — 10-Q · 2025-11-05T00:00:00.000Z [bearish] Risk: high
  Gossamer Bio, Inc. (GOSS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $123.1 million, a substantial rise
• Gossamer Bio Reports Unregistered Equity Sales — 8-K · 2025-09-25T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. filed an 8-K on September 25, 2025, reporting unregistered sales of equity securities on September 24, 2025. The filing does not provide spec
• Gossamer Bio Narrows Q2 Loss Amidst Zero Revenue — 10-Q · 2025-08-05T00:00:00.000Z [bearish] Risk: high
  Gossamer Bio, Inc. reported no revenue from contracts with collaborators for the three and six months ended June 30, 2025, consistent with the prior year's peri
• Gossamer Bio Files 8-K: Board Changes & Shareholder Votes — 8-K · 2025-06-25T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. announced on June 25, 2025, changes in its board of directors and executive compensation arrangements. The filing also covers the submission
• Gossamer Bio Files 8-K Report — 8-K · 2025-06-16T00:00:00.000Z [neutral] Risk: low
  On June 16, 2025, Gossamer Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific financial fi
• Gossamer Bio Files 8-K on Financials — 8-K · 2025-05-15T00:00:00.000Z [neutral] Risk: low
  Gossamer Bio, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Gossamer Bio: Executive Compensation & Equity Awards Detailed — DEF 14A · 2025-04-29T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation and equity awards for the fiscal year ending December 31, 2024. The filin
• Gossamer Bio Files 2024 10-K — 10-K · 2025-03-13T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. filed its 2024 10-K on March 13, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorpo
• Gossamer Bio Files 8-K for Other Events — 8-K · 2025-02-19T00:00:00.000Z [neutral] Risk: low
  Gossamer Bio, Inc. filed an 8-K on February 19, 2025, to report other events. The filing does not contain specific details about the nature of these events, but
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• Gossamer Bio Files Q3 2024 10-Q — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported revenue from contracts with collaborators and license and servi
• Gossamer Bio Faces Nasdaq Delisting Notice — 8-K · 2024-09-13T00:00:00.000Z [bearish] Risk: high
  Gossamer Bio, Inc. announced on September 11, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The com
• Gossamer Bio Reports Flat Q2 Revenue — 10-Q · 2024-08-12T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue from contracts with collaborators of $0.0 million for the se
• SC 13G/A Filing — SC 13G/A · 2024-08-02T00:00:00.000Z [neutral]
• Gossamer Bio to be Acquired by Cerberus for $1.2B — 8-K · 2024-07-18T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. announced on July 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Cerberus Capital Management, L.
• Gossamer Bio Reports on Shareholder Vote Matters — 8-K · 2024-06-10T00:00:00.000Z [neutral] Risk: low
  Gossamer Bio, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders on June 6, 2024. The filing details the company's
• Gossamer Bio Faces Delisting Concerns — 8-K · 2024-05-24T00:00:00.000Z [bearish] Risk: high
  Gossamer Bio, Inc. filed an 8-K on May 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company is base
• Gossamer Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-07T00:00:00.000Z [neutral] Risk: low
  Gossamer Bio, Inc. (GOSS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Gossamer Bio, Inc. filed a 10-Q report for the period ending March 31, 20
• Gossamer Bio Terminates J&J Agreement, Reports Equity Sales — 8-K · 2024-05-06T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. announced on May 3, 2024, the termination of its material definitive agreement with Johnson & Johnson Innovation LLC. The company also report
• Gossamer Bio, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · 2024-04-24T00:00:00.000Z [neutral] Risk: low
  Gossamer Bio, Inc. (GOSS) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Gossamer Bio, Inc. filed a DEF 14A form on April 24, 2024. The filin
• Gossamer Bio Appoints New CEO, Dr. Gujrathi Takes Helm — 8-K · 2024-03-12T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. announced on March 11, 2024, the appointment of Dr. Sheila Gujrathi as Chief Executive Officer and a member of the Board of Directors, effect
• Gossamer Bio, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-05T00:00:00.000Z [neutral] Risk: medium
  Gossamer Bio, Inc. (GOSS) filed a Annual Report (10-K) with the SEC on March 5, 2024. Gossamer Bio, Inc. filed its 2023 Form 10-K on March 5, 2024, reporting on
• Roivant to Acquire Gossamer Bio for $1.7B — 8-K · 2024-03-04T00:00:00.000Z [bullish] Risk: medium
  Gossamer Bio, Inc. announced on March 4, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of The Roivant Sciences Ltd. for $
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• ARCH Venture Fund IX Exits Gossamer Bio Position — SC 13G/A · 2024-02-09T00:00:00.000Z [bearish] Risk: medium
  ARCH Venture Fund IX, L.P. and its affiliates, including ARCH Venture Partners IX, L.P. and ARCH Venture Partners IX, LLC, have filed an SC 13G/A indicating the
• FMR LLC & Abigail Johnson Disclose 5.44% Stake in Gossamer Bio — SC 13G · 2024-02-09T00:00:00.000Z [bullish] Risk: low
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have disclosed a 5.440% beneficial ownership stake in Gossamer Bio, Inc., totaling 12,263,918
• Millennium Management Amends Gossamer Bio Stake — SC 13G/A · 2024-01-11T00:00:00.000Z [neutral]
  Millennium Management LLC, a Delaware-based investment firm, filed an amended SC 13G/A on January 11, 2024, disclosing its ownership of Gossamer Bio, Inc. commo
• Artal Group & Invus Disclose Significant Stake in Gossamer Bio — SC 13G · 2024-01-11T00:00:00.000Z [neutral]
  Artal International S.C.A. and its affiliated entities, including Invus Public Equities, L.P., have reported their beneficial ownership in Gossamer Bio, Inc. (N